Source comparison
BPC-157 Research Mental Performance: Compound Comparison
BPC-157 Dopamine/GABA modulation, NO pathway stabilisation, BDNF upregulation Unknown; intranasal may bypass None. Cognitive endpoints not tested in humans 200–500 μg SC daily Neuroprotective potential demonstrated in animal TBI models but zero human performan
This comparison does not assign a generated winner or score.
- BPC-157
- Dopamine/GABA modulation, NO pathway stabilisation, BDNF upregulation
- Unknown; intranasal may bypass
- None. Cognitive endpoints not tested in humans
- 200–500 μg SC daily
- Neuroprotective potential demonstrated in animal TBI models but zero human performance trials. Cognitive claims are mechanistic speculation
- Semax
- BDNF/NGF elevation, ACTH fragment, modulates dopamine/serotonin
- Yes (intranasal)
- Limited human trials show improved attention in stroke recovery; no healthy-subject performance data
- 300–600 μg IN daily
- Established intranasal bioavailability and some human neurological data but not rigorously tested for cognitive enhancement in healthy populations
- Cerebrolysin
- Neurotrophic peptide mixture derived from porcine brain
- Yes (IV)
- Multiple human trials in stroke, TBI, dementia. Cognitive improvement vs placebo in disease states
- 10–30 mL IV
- Only peptide in this table with substantial human cognitive trial data, but limited to pathological populations. Not studied in healthy enhancement contexts
- Noopept
- Modulates AMPA/NMDA receptors, increases BDNF/NGF
- Yes (oral)
- Russian studies show memory improvements; Western replication minimal
- 10–30 mg oral daily
- More human cognitive data than BPC-157 but methodological concerns limit confidence. Replication by independent Western labs is scarce